ArticleBrain & spine2025
Shared metabolomic signatures for prognostic precision across brain injuries.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Introduction: Metabolomic alterations have been linked to a range of neurological conditions. Investigating temporal changes in serum metabolomic profiles, regardless of the type of brain injury may reveal prognostic indicators. Research question: We hypothesize that specific metabolomic signatures, conserved across different acute brain injuries, can serve as robust predictors of patient outcomes. Material and methods: In this longitudinal prospective observational study, serum samples were collected early (2 ± 1 day) and late (6 ± 2 days) post-injury from a total of 73 patients with ischemic stroke (n = 30), aneurysmal subarachnoid hemorrhage (n = 30), and traumatic brain injury (n = 13). Outcomes were categorized as favorable (modified Rankin Scores (mRS) 0-3) and unfavorable (mRS 4-6) three months post-injury. Metabolomic profiling (Orbitrap mass spectrometry) of 462 metabolites, analyzed using statistical and machine learning methods, identified significant outcome differences (p < 0.05, FDR-corrected). Results: Early-stage samples indicated good prognostic power with a combination of uridine, tryptophan, and lactic acid (AUC 88.8 %, OR 5.29, p < 0.0001). Late-stage samples showed high discriminatory accuracy with a combination of prostaglandin J2, gamma-linolenic acid, N-acetyl-L-alanine, uridine, N-alpha-acetyl-L-asparagine, 3-hydroxy-3-methylglutarate, propionate, and creatinine (AUC 94.4 %, OR 14.5, p < 0.0001). Pathway analyses revealed significant associations with glycolysis/gluconeogenesis, pyrimidine metabolism, and tryptophan metabolism at early stages, and fatty acid biosynthesis, pyruvate metabolism, phenylalanine metabolism, and tryptophan metabolism at later stages. Discussion and conclusion: These findings underscore the dynamic nature of metabolomic profiles in acute brain injuries and highlight common metabolites as significant prognostic markers across brain injury types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.